Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
29.32 ^USD	+1.35%		-0.27%	-9.23%

Apr. 11	Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	MT
Apr. 03	Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	MT

Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024

February 22, 2024 at 07:30 am EST

Harmony Biosciences Holdings, Inc. provided revenue guidance for the year 2024. For the year, the company expects net product revenue to be between $700 million to $720 million.

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	Apr. 11	MT
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	Apr. 03	MT
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	Apr. 03	CI
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	Mar. 19	MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:35 PM	Mar. 12
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	Feb. 27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	Feb. 23	MT
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	Feb. 22	MT
Transcript : Harmony Biosciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Feb. 22	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91	Feb. 22	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024	Feb. 22	CI
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application	Feb. 21	MT
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy	Feb. 21	CI
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome	Feb. 20	MT
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome	Feb. 20	DJ
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating	Feb. 15	MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Harmony Biosciences Preliminary Q4 Results Show "Robust Momentum" for Narcolepsy-Related Drug, Oppenheimer Says	Jan. 10	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating	Jan. 09	MT
Harmony Biosciences Reports Higher Preliminary Q4 Revenue; Sets 2024 Revenue Outlook	Jan. 08	MT
Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024	Jan. 08	CI

Chart Harmony Biosciences Holdings, Inc.

Duration

Period

Chart Harmony Biosciences Holdings, Inc.

More charts

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harmony Biosciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.32 USD

Average target price

41.5 USD

Spread / Average Target

+41.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARMONY BIOSCIENCES HOLDINGS, INC.	-9.23%	1.67B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals